FindTrial
Sign In

Vaccination with IGN101 in patients with non-small-cell-lung-cancer (NSCLC)

Vaccination with IGN101 in patients with non-small-cell-lung-cancer (NSCLC)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-004592-11-IT
Enrollment
Unknown
Registered
2005-08-01
Start date
2005-02-16
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small-cell-lung-cancer stages IB, II A/B, III A MedDRA version: 6.1 Level: PT Classification code 10061873

Interventions

Product Name: IGN101 Product Code: NA Pharmaceutical Form: Solution for injection CAS Number: NA Current Sponsor code: IGN 101 Concentration unit: µg microgram(s) Concentration type: equal Concentrati

Sponsors

IGENEON
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026